Zacks: Analysts Expect Cellular Biomedicine Group Inc (NASDAQ:CBMG) Will Post Earnings of -$0.53 Per Share

Share on StockTwits

Equities analysts expect that Cellular Biomedicine Group Inc (NASDAQ:CBMG) will report ($0.53) earnings per share (EPS) for the current quarter, according to Zacks. Zero analysts have made estimates for Cellular Biomedicine Group’s earnings, with estimates ranging from ($0.55) to ($0.50). Cellular Biomedicine Group also reported earnings of ($0.53) per share during the same quarter last year. The firm is scheduled to announce its next quarterly earnings report on Wednesday, August 14th.

On average, analysts expect that Cellular Biomedicine Group will report full year earnings of ($2.08) per share for the current year, with EPS estimates ranging from ($2.28) to ($1.90). For the next year, analysts expect that the company will report earnings of ($2.01) per share, with EPS estimates ranging from ($2.05) to ($1.97). Zacks’ EPS averages are an average based on a survey of sell-side analysts that follow Cellular Biomedicine Group.

Cellular Biomedicine Group (NASDAQ:CBMG) last posted its quarterly earnings results on Tuesday, April 30th. The biotechnology company reported ($0.51) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.57) by $0.06. Cellular Biomedicine Group had a negative return on equity of 42.41% and a negative net margin of 17,921.62%. The firm had revenue of $0.05 million during the quarter.

Several equities research analysts have recently weighed in on CBMG shares. BidaskClub downgraded Westport Fuel Systems from a “buy” rating to a “hold” rating in a research report on Friday. Cantor Fitzgerald set a $33.00 price target on Aldeyra Therapeutics and gave the company a “buy” rating in a report on Tuesday, June 25th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $27.50.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Metropolitan Life Insurance Co. NY purchased a new stake in shares of Cellular Biomedicine Group during the fourth quarter worth $81,000. BNP Paribas Arbitrage SA raised its stake in shares of Cellular Biomedicine Group by 1,641.8% in the first quarter. BNP Paribas Arbitrage SA now owns 2,456 shares of the biotechnology company’s stock valued at $42,000 after acquiring an additional 2,315 shares during the last quarter. Nikko Asset Management Americas Inc. bought a new position in shares of Cellular Biomedicine Group in the first quarter valued at approximately $6,721,000. MetLife Investment Advisors LLC bought a new position in shares of Cellular Biomedicine Group in the fourth quarter valued at approximately $110,000. Finally, Bank of New York Mellon Corp raised its stake in shares of Cellular Biomedicine Group by 16.3% in the fourth quarter. Bank of New York Mellon Corp now owns 37,857 shares of the biotechnology company’s stock valued at $669,000 after acquiring an additional 5,308 shares during the last quarter. Hedge funds and other institutional investors own 17.87% of the company’s stock.

Shares of NASDAQ CBMG traded down $0.14 on Wednesday, hitting $14.24. The company had a trading volume of 1,103 shares, compared to its average volume of 39,366. Cellular Biomedicine Group has a 12-month low of $12.04 and a 12-month high of $25.00. The company has a 50 day moving average price of $14.87. The firm has a market cap of $276.53 million, a price-to-earnings ratio of -7.11 and a beta of 2.57.

Cellular Biomedicine Group Company Profile

Cellular Biomedicine Group, Inc, a clinical stage biopharmaceutical company, develops therapies for cancer and degenerative diseases in Greater China. It focuses on developing and marketing cell-based therapies to treat various diseases, such as cancer and orthopedic diseases. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), a genetically modified T-cell receptors (TCRs), and next generation neoantigen-reactive tumor infiltrating lymphocytes; and human adipose-derived mesenchymal progenitor cells for the treatment of joint diseases.

Further Reading: What is the float in trading stocks?

Get a free copy of the Zacks research report on Cellular Biomedicine Group (CBMG)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Cellular Biomedicine Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellular Biomedicine Group and related companies with MarketBeat.com's FREE daily email newsletter.